

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
阿里健康信息技術有限公司
(Incorporated in Bermuda with limited liability)
(Stock code: 00241)

**FURTHER DELAY IN DESPATCH OF CIRCULAR REGARDING
REVISION OF ANNUAL CAPS OF
CONTINUING CONNECTED TRANSACTIONS**

Reference is made to (i) the announcement of Alibaba Health Information Technology Limited (the “**Company**”) dated November 21, 2017 in relation to, among other things, the revision of the annual caps of the non-exempt continuing connected transactions under the Services Framework Agreement, the Services Agreement and the Logistic Services Framework Agreement; (ii) the announcement of the Company dated December 5, 2017 in relation to the appointment of the Independent Financial Adviser (collectively, the “**Announcements**”); and (iii) the announcement of the Company dated December 22, 2017 in relation to the delay in despatch of the Circular (the “**Delay Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements and the Delay Announcement.

As disclosed in the Delay Announcement, the Circular containing, *inter alia*, further details of each of the Revised Annual Caps, the letter from the Independent Board Committee to the Independent Shareholders and the letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders, together with a notice of the SGM, is expected to be

despatched to the Shareholders on or around January 5, 2018. As more time is required to finalize certain information to be included in the Circular, the Company expects that the despatch date of the Circular will be further delayed to a date on or before January 12, 2018.

For and on behalf of the Board
Alibaba Health Information Technology Limited
WANG Lei
Chief Executive Officer and Executive Director

Hong Kong, January 5, 2018

As at the date of this announcement, the Board comprises seven Directors, of whom (i) one is an executive Director, namely Mr. WANG Lei; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. KANG Kai and Ms. ZHANG Yu; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.